TELA Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

21.04M

+19.22%

-0.182

-20.87%

21.27M

+14.84%

-0.160

-36%

22.59M

+11.82%

-0.150

-31.82%

Estimates Revision

The market is revising Downward the revenue expectations for TELA Bio, Inc. (TELA) for FY2025, with the revenue forecasts being adjusted by -2.91% over the past three months. During the same period, the stock price has changed by -28.76%.

Revenue Estimates for FY2025

Revise Downward

-2.91%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-0.48%

In Past 3 Month

Stock Price

Go Down

-28.76%

In Past 3 Month

4 Analyst Rating

Wall Street analysts forecast TELA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TELA is 4.06 USD with a low forecast of 1.25 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

1 Hold

0 Sell

Strong Buy

Current: 0.000

Low

1.25

Averages

4.06

High

6.00

Current: 0.000

Low

1.25

Averages

4.06

High

6.00

Canaccord

Buy

downgrade

$7 -> $4

2025-11-18

Reason

Canaccord

Price Target

$7 -> $4

2025-11-18

downgrade

Buy

Reason

Canaccord lowered the firm's price target on Tela Bio (TELA) to $4 from $7 and keeps a Buy rating on the shares. The firm said they posted a challenged Q3 as it missed top-line expectations and lowered full-year guidance, though it reiterated confidence in its commercial strategy and sales force structure as recent hires Jeffrey Blizzard and Jim Hagen from Abiomed (ABMD) become increasingly important pieces to the Tela Bio story.

Citizens JMP

Outperform

NULL

downgrade

$7 -> $5

2025-11-14

Reason

Citizens JMP

Price Target

$7 -> $5

2025-11-14

downgrade

Outperform

NULL

Reason

Citizens JMP lowered the firm's price target on Tela Bio to $5 from $7 and keeps an Outperform rating on the shares. Quarterly sales were shy of the Street by about 5%, reflecting several meaningful highlights, such as strong international sales and the addition of new customers, the analyst tells investors in a research note. The cons outweighed the pros, and management lowered its top-line guidance by 9% year over year, the firm adds.

Piper Sandler

Matt O'Brien

Neutral

downgrade

2025-11-14

Reason

Piper Sandler

Matt O'Brien

Price Target

2025-11-14

downgrade

Neutral

Reason

Piper Sandler analyst Matt O'Brien lowered the firm's price target on Tela Bio to $1.25 from $2 and keeps a Neutral rating on the shares. The firm notes the company reported Q3 results which missed its estimate on the top-line and on the operating loss side of things. Revenue guidance for the year was lowered, which is certainly a disappointing update, Piper adds.

Canaccord Genuity

Caitlin Cronin

Strong Buy

Maintains

$12 → $7

2025-03-21

Reason

Canaccord Genuity

Caitlin Cronin

Price Target

$12 → $7

2025-03-21

Maintains

Strong Buy

Reason

Canaccord lowered the firm's price target on Tela Bio to $7 from $12 and keeps a Buy rating on the shares. The firm said they posted a tough quarter significantly below consensus revenues as it lost a number of sales reps to competitors in the Q4 with the sales org already lean post commercial streamlining in the Q3. While the Q4 was a challenging one, the management team are experienced MedTech operators, and Canaccord believes they would need to see sustained sales org churn before becoming materially less constructive.

Piper Sandler

Matt O'Brien

Buy

Hold

Downgrades

$5 → $2

2025-03-21

Reason

Piper Sandler

Matt O'Brien

Price Target

$5 → $2

2025-03-21

Downgrades

Buy

Hold

Reason

Citizens Capital Markets

David Turkaly

Buy

Maintains

$12 → $7

2025-03-21

Reason

Citizens Capital Markets

David Turkaly

Price Target

$12 → $7

2025-03-21

Maintains

Buy

Reason

Citizens JMP lowered the firm's price target on Tela Bio to $7 from $12 and keeps an Outperform rating on the shares. Sales in the quarter were impacted by several factors, including competitive rep poaching by smaller wound care companies offering significant comp benefits including guaranteed contracts, the analyst tells investors in a research note. The firm still believes that Tela's two main biologic product platforms provide significant benefits to all constituents and that the premium growth profile here should be sustainable.

Valuation Metrics

The current forward P/E ratio for TELA Bio Inc (TELA.O) is -1.82, compared to its 5-year average forward P/E of -4.32. For a more detailed relative valuation and DCF analysis to assess TELA Bio Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.32

Current PE

-1.82

Overvalued PE

-2.67

Undervalued PE

-5.96

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-5.38

Current EV/EBITDA

-3.07

Overvalued EV/EBITDA

-3.21

Undervalued EV/EBITDA

-7.55

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

2.87

Current PS

0.57

Overvalued PS

4.76

Undervalued PS

0.98

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

TELA News & Events

Events Timeline

No data

News

7.0

2025-12-23Benzinga

BDX Faces Monopoly Allegations in U.S. Hernia Mesh Market, Impacting Patient Choices

7.0

2025-12-22SeekingAlpha

Becton, Dickinson Faces Allegations of Stifling Competition in Hernia Mesh Industry

5.0

2025-12-12Globenewswire

TELA Bio Grants 3,600 Restricted Stock Units to New Employees

People Also Watch

Frequently Asked Questions

What is TELA Bio Inc (TELA) stock price today?

The current price of TELA is 1.09 USD — it has decreased -2.68 % in the last trading day.

What is TELA Bio Inc (TELA)'s business?

TELA Bio, Inc. is a commercial-stage medical technology company. The Company is focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. Its first portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), addresses unmet needs in hernia repair and abdominal wall reconstruction. Its OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair. The Company's OviTex products include OviTex 1S, OviTex 2S, OviTex LPR, and OviTex IHR. Its second portfolio of products, the OviTex PRS Reinforced Tissue Matrix (OviTex PRS), addresses unmet needs in plastic and reconstructive surgery. OviTex PRS is indicated for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft-tissue repair.

What is the price predicton of TELA Stock?

What is TELA Bio Inc (TELA)'s revenue for the last quarter?

TELA Bio Inc revenue for the last quarter amounts to 20.69M USD, increased 9.14 % YoY.

What is TELA Bio Inc (TELA)'s earnings per share (EPS) for the last quarter?

TELA Bio Inc. EPS for the last quarter amounts to -0.19 USD, decreased -54.76 % YoY.

What changes have occurred in the market's expectations for TELA Bio Inc (TELA)'s fundamentals?

How many employees does TELA Bio Inc (TELA). have?

TELA Bio Inc (TELA) has 209 emplpoyees as of January 08 2026.

What is TELA Bio Inc (TELA) market cap?

Today TELA has the market capitalization of 49.87M USD.